Skip to search formSkip to main contentSkip to account menu

bevirimat

Known as: 3-O-(3',3'-dimethylsuccinyl) betulinic acid, 3-O-(3',3'-dimethylsuccinyl)betulinic acid 
A drug derived from a betulinic acid-like compound, first isolated from the Chinese herb Syzygium claviflorum, with activity against human… 
National Institutes of Health

Related topics

Related topics

5 relations
Bevirimat Dimeglumine

Narrower (2)

MPC-4326PA-457

Broader (2)

SuccinatesTriterpenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Synthesis and properties of 2-cyanoethoxy derivatives of dammarane triterpenoids
Cyanoethylation of dammaran-3β-ols and 3-oxime dammarene, semisynthetic derivatives of the natural dipterocarpol, afforded a… 
Review
2012
Review
2012
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
Protease-mediated maturation of HIV-1 virus particles is essential for virus infectivity. Maturation occurs concomitant with… 
2011
2011
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
BackgroundMaturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV… 
Highly Cited
2010
Highly Cited
2010
Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat
ABSTRACT Bevirimat (BVM) is the first of a new class of anti-HIV drugs with a novel mode of action known as maturation inhibitors… 
2010
2010
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates
Objective:Bevirimat is the first drug of a new class of antivirals that hamper the maturation of HIV. The objective of this study… 
2010
2010
In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by “Deep” Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1
ABSTRACT Initial in vitro studies of bevirimat resistance failed to observe mutations in the clinically significant QVT motif in… 
Review
2009
Review
2009
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
The recent availability of new antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection has… 
2008
2008
The Maturation Inhibitor Bevirimat (PA-457) can be Active in Patients Carrying HIV type-1 non-B Subtypes and Recombinants
Background Bevirimat (PA-457) is the first candidate of a new family of antiretroviral drugs, the maturation inhibitors. Its… 
Review
2007
Review
2007
Maturation inhibitors: a new therapeutic class targets the virus structure.
The current standard of care for HIV/AIDS in the developed world is HAART therapy, usually a combination of two reverse… 
Review
2006
Review
2006
Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)